MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2147/dmso.s552791

Медицинская библиотека · Diabetes, metabolic syndrome and obesity : targets and therapy · 2026

Dynamic Alterations of BMP9 in NAFLD: A Novel Hepatokine Marker of Metabolic Dysfunction and Disease Severity.

Cui Fan, Chen Fangmin, Dong Fanchao, Dong Jianjun

СтатьяПеревод в очереди

Аннотация

PURPOSE: Bone morphogenetic protein 9 (BMP9), a hepatokine belonging to the transforming growth factor-β (TGF-β) superfamily, plays a critical role in glucose and lipid metabolism. This study aimed to investigate the dynamic changes of BMP9 under metabolic stress in patients with different severities of non-alcoholic fatty liver disease (NAFLD), and to evaluate its associations with metabolic abnormalities and clinical diagnostic value.

PATIENTS AND

METHODS

A total of 84 participants were enrolled and categorized into normal control (Con), mild, moderate, and severe NAFLD groups. Standardized oral fat tolerance tests (OFTT) were conducted to assess dynamic alterations in circulating BMP9 and related metabolic indices. Trend analysis, Spearman correlation, multivariate regression, and receiver operating characteristic (ROC) curve analyses were performed to explore the relationships between BMP9 and metabolic parameters as well as its diagnostic performance.

RESULTS

Both fasting and postprandial BMP9 levels declined with increasing NAFLD severity, with a more pronounced reduction observed in the severe group (P < 0.05). In the severe NAFLD group, baseline BMP9 levels were reduced by 47.2%, and the time-integrated area under the concentration-time curve (AUC) was reduced by 52.7% compared with controls. The BMP9 AUC was negatively correlated with BMI, HOMA-IR, TG, and LDL-C, and positively correlated with HDL-C (all P < 0.05). Multivariate regression identified HOMA-IR and TG as independent predictors of lower BMP9 levels. Furthermore, ROC analysis demonstrated excellent diagnostic performance of BMP9 AUC in identifying moderate-to-severe NAFLD (ROC-AUC = 0.965).

CONCLUSION

BMP9 exhibits both basal deficiency and functional impairment in NAFLD and is closely associated with multiple metabolic abnormalities. Its dynamic profile may represent a promising early diagnostic biomarker for NAFLD and could potentially serve as a tool for metabolic disease screening and intervention.

Для цитирования: Cui Fan, Chen Fangmin, Dong Fanchao, Dong Jianjun. Dynamic Alterations of BMP9 in NAFLD: A Novel Hepatokine Marker of Metabolic Dysfunction and Disease Severity.. Diabetes, metabolic syndrome and obesity : targets and therapy. 2026. DOI: 10.2147/dmso.s552791.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.